Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/12/2007 First Published: 6/1/2000


1.		Phase III Randomized Study of Oral Nitrocamptothecin Versus Gemcitabine in Chemotherapy-Naive Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Pharmaceutical / Industry				SUPERGEN-RFS2000-02 NCT00005869

Last Modified: 6/12/2007 First Published: 6/1/2000


2.		Phase III Randomized Study of Oral Nitrocamptothecin Versus Most Appropriate Chemotherapy in Patients With Recurrent or Refractory Adenocarcinoma of the Pancreas (Summary Last Modified 12/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Pharmaceutical / Industry				SUPERGEN-RFS2000-09 RPCI-DS-99-11, NCT00005870

Last Modified: 6/12/2007 First Published: 6/1/2000


3.		Phase III Randomized Study of Nitrocamptothecin Versus Fluorouracil in Patients With Recurrent or Refractory Pancreatic Cancer (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Pharmaceutical / Industry				SUPERGEN-RFS2000-06 PCI-99-001, NCT00005871

Last Modified: 4/1/2000


4.		Phase II Study of Oral Nitrocamptothecin in Advanced Pancreatic Adenocarcinoma (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				SFFCR-IND-45-952 NCI-V96-0998

Last Modified: 9/26/2006 First Published: 6/1/2000


5.		Phase II Study of Nitrocamptothecin in Patients With Stage IV, Hormone Refractory Prostate Cancer (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				CLB-99901 GUMC-00192, NCT00005820, CALGB-99901

Last Modified: 11/1/2000 First Published: 6/1/2000


6.		Phase II Study of Nitrocamptothecin in Patients With Glioblastoma Multiforme (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								EORTC-16996G NCT00005826

Last Modified: 9/1/2001 First Published: 6/1/2000


7.		Phase II Study of Nitrocamptothecin in Patients With Non-Small Cell Lung Cancer (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SUPERGEN-RFS2000-16 DFCI-99184, NCT00005872

Last Modified: 9/1/2001 First Published: 6/1/2000


8.		Phase II Study of Nitrocamptothecin in Patients With Locally Recurrent or Metastatic Breast Cancer (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				Pharmaceutical / Industry				SUPERGEN-RFS2000-17 IUMC-9906-11, NCT00005873

Last Modified: 9/1/2001 First Published: 6/1/2000


9.		Phase II Study of Nitrocamptothecin in Patients With Locally Advanced or Metastatic Gastrointestinal Leiomyosarcomas or Other Soft Tissue Sarcomas (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				Pharmaceutical / Industry				SUPERGEN-RFS2000-24 MDA-DM-99109, NCT00005874

Last Modified: 9/1/2001 First Published: 6/1/2000


10.		Phase II Study of Nitrocamptothecin in Patients With Metastatic Melanoma (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Over 16				Pharmaceutical / Industry				SUPERGEN-RFS2000-10 MDA-DM-98237, NCT00005875

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute